Clinical Trial Update: The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating how blocking AMPA receptors modulates ketamine's anti-suicidal effects; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Depressive Disorder
• Major Depressive Disorder
• Post-traumatic Stress Disorder
• Suicidal Ideation

Drugs mentioned

• AMPA receptor blocker
• Ketamine (ketamine)

Snippet

Sponsor: Yale University | Conditions: Depressive Disorder, Major Depressive Disorder | Phase 2 | Status: RECRUITING